Clinical trial
a Multicenter Phase II Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.
NCT07616362 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- a Multicenter Phase II Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.
- Lead sponsor
- Federation Francophone de Cancerologie Digestive
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- June 30, 2026
- Completion date
- April 30, 2031
- Enrollment
- 110 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
borderline resectable pancreatic ductal adenocarcinoma